These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10649562)

  • 1. Neurodegeneration in the polyglutamine diseases: Act 1, Scene 1.
    Nussbaum R; Auburger G
    Nat Neurosci; 2000 Feb; 3(2):103-4. PubMed ID: 10649562
    [No Abstract]   [Full Text] [Related]  

  • 2. The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1).
    Orr HT
    Neurobiol Dis; 2000 Jun; 7(3):129-34. PubMed ID: 10860780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human.
    Huynh DP; Figueroa K; Hoang N; Pulst SM
    Nat Genet; 2000 Sep; 26(1):44-50. PubMed ID: 10973246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making degeneration specific.
    Narasimhan K
    Nat Med; 2001 Nov; 7(11):1184. PubMed ID: 11689879
    [No Abstract]   [Full Text] [Related]  

  • 5. Dynamic regulation of molecular chaperone gene expression in polyglutamine disease.
    Huen NY; Chan HY
    Biochem Biophys Res Commun; 2005 Sep; 334(4):1074-84. PubMed ID: 16039613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells.
    Ishikawa K; Owada K; Ishida K; Fujigasaki H; Shun Li M; Tsunemi T; Ohkoshi N; Toru S; Mizutani T; Hayashi M; Arai N; Hasegawa K; Kawanami T; Kato T; Makifuchi T; Shoji S; Tanabe T; Mizusawa H
    Neurology; 2001 Jun; 56(12):1753-6. PubMed ID: 11425948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
    Xia H; Mao Q; Eliason SL; Harper SQ; Martins IH; Orr HT; Paulson HL; Yang L; Kotin RM; Davidson BL
    Nat Med; 2004 Aug; 10(8):816-20. PubMed ID: 15235598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The advances in research on phosphorylation of polyglutamine disease].
    Zhou YF; Jiang H; Tang JG; Tang BS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats.
    Ansorge O; Giunti P; Michalik A; Van Broeckhoven C; Harding B; Wood N; Scaravilli F
    Ann Neurol; 2004 Sep; 56(3):448-52. PubMed ID: 15349877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomedicine. Ataxin-1 regulators in the spotlight.
    Heintz N
    Science; 2003 Jul; 301(5629):59-60. PubMed ID: 12843383
    [No Abstract]   [Full Text] [Related]  

  • 11. Transcriptional alterations and chromatin remodeling in polyglutamine diseases.
    Helmlinger D; Tora L; Devys D
    Trends Genet; 2006 Oct; 22(10):562-70. PubMed ID: 16911843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional differences of somatic CAG repeat instability do not account for selective neuronal vulnerability in a knock-in mouse model of SCA1.
    Watase K; Venken KJ; Sun Y; Orr HT; Zoghbi HY
    Hum Mol Genet; 2003 Nov; 12(21):2789-95. PubMed ID: 12952864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration.
    Watase K; Weeber EJ; Xu B; Antalffy B; Yuva-Paylor L; Hashimoto K; Kano M; Atkinson R; Sun Y; Armstrong DL; Sweatt JD; Orr HT; Paylor R; Zoghbi HY
    Neuron; 2002 Jun; 34(6):905-19. PubMed ID: 12086639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling human trinucleotide repeat diseases in Drosophila.
    Yu Z; Bonini NM
    Int Rev Neurobiol; 2011; 99():191-212. PubMed ID: 21906541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of Purkinje cell pathology in SCA1 transgenic mice by p53 deletion.
    Shahbazian MD; Orr HT; Zoghbi HY
    Neurobiol Dis; 2001 Dec; 8(6):974-81. PubMed ID: 11741393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17.
    Shah AG; Friedman MJ; Huang S; Roberts M; Li XJ; Li S
    Hum Mol Genet; 2009 Nov; 18(21):4141-52. PubMed ID: 19643914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of chromatin alterations in neurodegeneration induced by polyglutamine-expanded ataxin-7].
    Helmlinger D; Tora L; Devys D
    Med Sci (Paris); 2006; 22(8-9):700-2. PubMed ID: 16962040
    [No Abstract]   [Full Text] [Related]  

  • 18. Overexpression of HGF attenuates the degeneration of Purkinje cells and Bergmann glia in a knockin mouse model of spinocerebellar ataxia type 7.
    Noma S; Ohya-Shimada W; Kanai M; Ueda K; Nakamura T; Funakoshi H
    Neurosci Res; 2012 Jun; 73(2):115-21. PubMed ID: 22426494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAG repeat disorder models and human neuropathology: similarities and differences.
    Yamada M; Sato T; Tsuji S; Takahashi H
    Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
    Bowman AB; Yoo SY; Dantuma NP; Zoghbi HY
    Hum Mol Genet; 2005 Mar; 14(5):679-91. PubMed ID: 15661755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.